Advertisement
| jnj annual report 2023: Greener Products Al Iannuzzi, 2024-08-21 Sustainability and its competitive advantage are the goals of every company and any brand that wants to stay successful in the marketplace. Customers also gravitate to brands that manage sustainability issues well. Greener Products: The Making and Marketing of Sustainable Brands written by a renowned sustainability expert, continues to address the latest developments in the extremely fast-moving field of sustainability. The third edition is thoroughly updated, introduces new case studies, and includes a new chapter on green marketing. With over 40 case studies, it explores the best practices of leading global companies and helps readers learn what it is that makes them successful. New in the Third Edition: Presents, in a practical way, the best practices of sustainable brands in a global economy. Addresses the most current sustainability topics like circular economy, plastics in the environment, biodiversity, climate change, green chemistry, etc. Includes current marketing information on consumer trends to purchase greener products. Incorporates the latest pressures on companies to address sustainability, retailer programs, business-to-business expectations, ESG raters, rankers, and stock funds. Covers best practices of companies from various industries on how to make and market greener products. Provides current tools for making products more sustainable and methods on how to market sustainable improvements. Includes lecture slides available upon request for use in the classroom. This book serves senior undergraduate and graduate students in programs focused on sustainability, as well as academics and corporate sustainability leaders. The previous versions have been used to teach courses on sustainability, product improvement, introduction to sustainability, green marketing and sustainability, and sustainability policy. Any university that teaches a course on sustainability and any company or individual interested in making and marketing more sustainable products would benefit from the new edition of this book. |
| jnj annual report 2023: Sustainability Programs William Borges, John Grosskopf, 2025-03-27 Go-to guidance for designing, implementing, and managing effective sustainability programs and their management systems Moving past vague concepts, buzzword overloads, superficial efforts, and flavor-of-the-month misdirections, Sustainability Programs presents a pragmatic, step-by-step approach to creating and managing adaptable, organization-wide sustainability programs to achieve People, Planet, and Profit (3P) objectives with least cost, effort, and risk. Key steps covered in this book include reaching a programmatic “Go” decision, developing sustainability policies, designing an organizational framework, defining the most pressing sustainability needs, and cascading 3P goals, tactics, targets, and initiatives into business units, functions, and departments to create new capabilities and improve performance. By following the principles and practices in this book, any organization can better achieve sustainability’s full promise of social responsibility, environmental stewardship, and financial performance. Written by authors with a wealth of practitioner experience in the field, Sustainability Programs explores topics including: Creating social, environmental, and financial strategies, tactics, targets, and initiatives that create new capabilities and resolve 3P performance issues Avoiding ad hoc projects that fail to address critical sustainability issues, wasting valuable resources and squandering competitive advantages Overcoming technical professionals’ lack of business management experience and helping management professionals understand sustainability’s benefits and intricacies Understanding sustainability through the management lenses of risk reduction, improved efficiencies through eradication of wastes, increased revenues via innovation, and enhanced competitive advantages fueled by greenwash-free transparency. Responding to the demanding data capture, analysis, and reporting challenges of environmental, social, and governance (ESG). Acknowledging that one size does not fit all, this book delivers individual concepts and methods adaptable across any organization’s value chains. It is an essential read for leaders and practitioners working within private and public enterprises of all types and sizes, especially those with 2,000 to 5,000 employees. |
| jnj annual report 2023: Social Innovation Design Cases Vijay K. Vaishnavi, 2024-08-14 Social innovation is an innovation whose main aim is to benefit society. There is a worldwide need for and interest in conducting innovations and social innovations. Social Innovation Design Cases: A Chronicle of Global Journeys provides an in-depth description of the design journeys of twenty social innovation cases from twelve countries around the globe on five continents. The design cases span areas ranging from promoting rural economic development to addressing climate change. The book describes in depth, citing relevant references, the design journeys of the twenty social innovations and corresponding social enterprises, following an innovation design process model. Additionally, it describes the knowledge models and metamodels contributed by these cases. Each design case presents the overall business model of the social innovation and the corresponding social enterprise. The book is for social entrepreneurs, innovators and aspiring innovators, especially those actively planning and designing social innovations in for-profit, government and not-for-profit organizations. In addition to managers, executives and mid-level staff, the book is for students and trainees who would like to understand different kinds of social innovations as well as their design and implementation. Providing details on the design and implementation of a variety of successful social innovations, the cases presented can serve as templates for future social innovations. The book can empower social entrepreneurs and innovators to develop and implement ideas for the betterment of society at large. |
| jnj annual report 2023: Cases on Transformational Entrepreneurship Gideon Maas, Andrew Johnston, 2024-07-05 This book brings together a wealth of international case studies to examine transformational entrepreneurship and its multifaceted applications across different sectors, including the arts, business, engineering, government, healthcare, and nonprofits. Contributors illustrate how this distinct form of entrepreneurship can adapt to unpredictable changes, balancing social and economic impact to promote stability and growth. |
| jnj annual report 2023: Annual Report to the Justices of the Supreme Judicial Court Massachusetts. Supreme Judicial Court. Office of the Executive Secretary, 1960 |
| jnj annual report 2023: Curious Future Insight Ulrich A.K. Betz, 2023-12-30 This book follows up the debate on the future of science and technology at the Curious2022 – Future Insight Conference, the second event in this conference series initiated on the occasion of Merck’s 350th anniversary. In the chapters, some of the world’s top scientists, managers and entrepreneurs explore breakthrough technologies and how they can be applied to make a better world for humanity. The book begins with an introduction to the vision of the conference “United by science for a better tomorrow” and the impacts caused by the pandemic, highlighting the importance of gathering like-minded people to discuss and support the advancement of science and technology for the benefit of humanity. In the first part of the book, readers will also find a chapter written by the Executive Board of Merck KGaA discussing the importance of curiosity for innovation and an overview of the company’s contribution in the areas of life sciences, healthcare and electronics forward-moving the scientific discovery. The second part of the book offers insights of some of the scientific topics discussed at the conference, and particular attention is given to new therapies and sustainability. In the final part of the book, readers will find some thoughts on ethical principles guiding our application of science and technology to create a bright future for humanity, and diverse perspectives on topics such as health, life sciences, nutrition, material sciences, digitalization, AI, energy, mobility, space flight, robotics, the secrets of the human mind and new ways of working together. Given its interdisciplinary appeal, the book will inspire curiosity in a wide readership, from scholars and researchers to professionals with an interest in exploring the future of science and technology, solving the problems of today, and paving the way for a better tomorrow. Chapters 1 and 2 are available open access under a Creative Commons Attribution 4.0 International License via link.springer.com |
| jnj annual report 2023: Pension Funds and Sustainable Investment P. Brett Hammond, Raimond Maurer, Olivia S. Mitchell, 2023-04-15 This is an open access title available under the terms of a CC BY-NC-ND 4.0 International licence. It is free to read at Oxford Scholarship Online and offered as a free PDF download from OUP and selected open access locations. Since its green shoots first emerged around 50 years ago, acceptance of environmental, social, and governance (ESG) considerations in institutional investing-especially at pension funds-has evolved with distinct shifts in investor preferences. This Pension Research Council volume traces these shifts and their implications, leading up to the present day. The book notes that investors have diverse reasons for devoting attention to ESG criteria when deciding where to invest their money. Some had religious motives, such as Quakers who focused on values; this approach can offer some risk mitigation. Nevertheless, studies that look at whether divestment actually changes companies' behaviors show that this rarely occurs. Accordingly, this book offers a variety of distinct viewpoints from a variety of countries, on whether, how, and when ESG criteria should, and should not, drive pension fund investments. The authors also find that policymakers should consider fund consolidation in private sector retirement systems, along with whether service-provider incentives could be better be aligned with sustainability incentives. For instance, boosting transparency in these markets would help generate better-informed policies, while providing beneficiaries with information relevant to their savings choices. |
| jnj annual report 2023: Corporate Financialization Marcelo José do Carmo, Mário Sacomano Neto, Julio Cesar Donadone, 2023-03-30 The economic process of financialization is defined by many as the development of the dependence and subordination of the productive sector to the financial sector. Leading to an emphasis on maximizing shareholder value above all else, the financialization of the economy and production has an enormous impact on the everyday life of ordinary people including the erosion of employment right, the rise of precarious work, and rising inequalities. Using multicase study research and an exploratory approach, this book analyzes the financialization process in the ten companies with the highest market capitalization worldwide including tech firms, oil companies and banks. This book analyzes indicators of financialization in large corporations including a comparison between profitability sources; shareholding structure, acquisitions and sales of shares; mergers and acquisitions; the origins of directors; payment of compensation to executives; dividend payments to shareholders and stock repurchases; employee salaries; and employment levels. The data demonstrates that what would once have been considered non-core business activities have become more profitable than core business activities in many of these companies. In some cases, these companies are responsible for large investment funds and financial-type institutions which already surpass the largest banks in terms of assets under management. Meanwhile, the average salaries at some of these companies have been falling in real terms due to the rise of outsourcing and the use of cheap or precarious labour. Adopting an economic sociology approach, this book marks a significant contribution to the literature on financialization in economics, sociology and business. |
| jnj annual report 2023: The Corporation in the Twenty-First Century John Kay, 2024-08-22 SHORTLISTED FOR THE FINANCIAL TIMES AND SCHRODERS BUSINESS BOOK OF THE YEAR 2024 Original and thought-provoking... A brilliantly erudite account of the major waves in the theory and practice of management - The Financial Times The doyen of British thinkers on the evolution of business...One of the great attractions of his [work] is that he stands above and apart from conventional political attitudes - Literary Review For generations, we have defined a corporation as a business run by a capitalist elite, that uses its accumulated wealth to own the means of production and exercise economic power. That is no longer the reality. In the twenty-first century, our most desired goods and services aren't stacked in warehouses or on container ships: they appear on your screen, fit in your pocket or occupy your head. But even as we consume more than ever before, big business faces a crisis of legitimacy. The pharmaceutical industry creates life-saving vaccines but has lost the trust of the public. The widening pay gap between executives and employees is destabilising our societies. Facebook and Google have more customers than any companies in history but are widely reviled. John Kay, one of the greatest economists of our time, describes how the pursuit of shareholder value has destroyed some of the leading companies of the twentieth century. Incisive and provocative, this book redefines successful commercial activity and leadership, the knowledge economy and what the future of the modern corporation might be. |
| jnj annual report 2023: Leadership in the Pharmaceutical Industry Nataliia Aliekperova, 2025-04-21 Leadership in the Pharmaceutical Industry focuses on leadership in pharmaceutical organisations at three levels: individual, team, and organisational. At the individual level, it covers leadership basics, theories, types of leaders, differences between leaders and managers, leadership traits and skills, and systems thinking. At the team level, it explores leadership styles, the leader’s interaction with the team, and employee motivation, including the use of intrinsic motivational factors. At the organisational level, it examines the leader’s role in creating and maintaining organisational culture, forming and implementing organisational strategy, and managing organisational changes. The book also addresses the specifics of the pharmaceutical industry, including the types and characteristics of innovations and the ethics of leader behaviour, emphasising the importance of ethical leadership. Notably, leadership issues are illustrated with practical cases featuring prominent leaders such as Paul Janssen, Daniel Vasella, Charles Walgreen III, John C. Martin, Roy Vagelos, Albert Bourla, Kiran Mazumdar-Shaw, and Filya Zhebrovska. These leaders were or are involved in creating, manufacturing, and providing patients with pharmaceutical products. The book is designed to benefit readers from various business sectors, with the primary audience being academics, students, and individuals interested in leadership in the pharmaceutical industry. |
| jnj annual report 2023: Globalization C. Gopinath, 2023-01-17 Globalization: A Multi-Dimensional System provides a comprehensive understanding of the complex process of globalization and how it impacts nations, organizations and individuals who operate in its environment. C. Gopinath addresses why some nations welcome its benefits whilst others seek protection from it and provides an insightful look into arguments for and against globalization. |
| jnj annual report 2023: Care Premilla Nadasen, 2023-10-10 An eye-opening reckoning with the care economy, from its roots in racial capitalism to its exponential growth as a new site of profit and extraction. Since the earliest days of the pandemic, care work has been thrust into the national spotlight. The notion of care seems simple enough. Care is about nurturing, feeding, nursing, assisting, and loving human beings. It is “the work that makes all other work possible.” But as historian Premilla Nadasen argues, we have only begun to understand the massive role it plays in our lives and our economy. Nadasen traces the rise of the care economy, from its roots in slavery, where there was no clear division between production and social reproduction, to the present care crisis, experienced acutely by more and more Americans. Today’s care economy, Nadasen shows, is an institutionalized, hierarchical system in which some people’s pain translates into other people’s profit. Yet this is also a story of resistance. Low-wage workers, immigrants, and women of color in movements from Wages for Housework and Welfare Rights to the Movement for Black Lives have continued to fight for and practice collective care. These groups help us envision how, given the challenges before us, we can create a caring world as part of a radical future. |
| jnj annual report 2023: Freedom in the World 2023 Freedom House, 2024-05-20 The annual Freedom in the World is the standard-setting comparative assessment of global political rights and civil liberties. The methodology of this survey is derived in large measure from the Universal Declaration of Human Rights, and these standards are applied to all countries and territories. |
| jnj annual report 2023: Accessions of Unlimited Distribution Reports , 1972-10-13 |
| jnj annual report 2023: A Proposal to End the COVID-19 Pandemic Ruchir Agarwal, Ms. Gita Gopinath, 2021-05-19 Urgent steps are needed to arrest the rising human toll and economic strain from the COVID-19 pandemic that are exacerbating already-diverging recoveries. Pandemic policy is also economic policy as there is no durable end to the economic crisis without an end to the health crisis. Building on existing initiatives, this paper proposes pragmatic actions at the national and multilateral level to expeditiously defeat the pandemic. The proposal targets: (1) vaccinating at least 40 percent of the population in all countries by the end of 2021 and at least 60 percent by the first half of 2022, (2) tracking and insuring against downside risks, and (3) ensuring widespread testing and tracing, maintaining adequate stocks of therapeutics, and enforcing public health measures in places where vaccine coverage is low. The benefits of such measures at about $9 trillion far outweigh the costs which are estimated to be around $50 billion—of which $35 billion should be paid by grants from donors and the residual by national governments potentially with the support of concessional financing from bilateral and multilateral agencies. The grant funding gap identified by the Access to COVID-19 Tools (ACT) Accelerator amounts to about $22 billion, which the G20 recognizes as important to address. This leaves an estimated $13 billion in additional grant contributions needed to finance our proposal. Importantly, the strategy requires global cooperation to secure upfront financing, upfront vaccine donations, and at-risk investment to insure against downside risks for the world. |
| jnj annual report 2023: Contemporary Business Louis E. Boone, David L. Kurtz, Michael H. Khan, Brahm Canzer, Rosalie Harms, Peter M. Moreira, 2023-05-15 Enable students to evaluate and provide solutions to today's global business challenges and thrive in today's fast-paced business environment. Rooted in the basics of business, Contemporary Business, 4th Canadian Edition provides students a foundation upon which to build a greater understanding of current business practices and issues that affect their lives. Written with attention toward global technology trends, and Environmental, Social, and Governance (ESG), Contemporary Business, 4th Canadian Edition encourages learners to grow and leverage intercultural aptitude, real-world problem-solving, and data analytics skills. |
| jnj annual report 2023: The Selection and Use of Essential Medicines WHO Expert Committee on the Selection and Use of Essential Medicines, 2004 This report presents the recommendations of the WHO Expert Committee responsible for updating the WHO Model List of Essential Medicines. The first part contains a progress report on the new procedures for updating the Model List and the development of the WHO Essential Medicines Library. It continues with a section on changes made in revising the Model List followed by a review of some sections such as hypertensive medicines and fast track procedures for deleting items. Annexes include the 13th version of the Model List and items on the list sorted according to their 5-level Anatomical Therapeutic Chemical classification codes. |
| jnj annual report 2023: Closing the Gap in a Generation WHO Commission on Social Determinants of Health, World Health Organization, 2008 Social justice is a matter of life and death. It affects the way people live, their consequent chance of illness, and their risk of premature death. We watch in wonder as life expectancy and good health continue to increase in parts of the world and in alarm as they fail to improve in others. |
| jnj annual report 2023: SQL Cookbook Anthony Molinaro, 2006 A guide to SQL covers such topics as retrieving records, metadata queries, working with strings, data arithmetic, date manipulation, reporting and warehousing, and hierarchical queries. |
| jnj annual report 2023: Artificial Intelligence and Games Georgios N. Yannakakis, Julian Togelius, 2025-07-04 This book covers artificial intelligence methods applied to games, both in research and game development. It is aimed at graduate students, researchers, game developers, and readers with a technical background interested in the intersection of AI and games. The book covers a range of AI methods, from traditional search, planning, and optimization, to modern machine learning methods, including diffusion models and large language models. It discusses applications to playing games, generating content, and modeling players, including use cases such as level generation, game testing, intelligent non-player characters, player retention, player experience analysis, and game adaptation. It also covers the use of games, including video games, to test and benchmark AI algorithms. The book is informed by decades of research and practice in the field and combines insights into game design with deep technical knowledge from the authors, who have pioneered many of the methods and approaches used in the field. This second edition of the 2018 textbook captures significant developments in AI and gaming over the past 7 years, incorporating advancements in computer vision, reinforcement learning, deep learning, and the emergence of transformer-based large language models and generative AI. The book has been reorganized to provide an updated overview of AI in games, with separate sections dedicated to AI’s core uses in playing and generating games, and modeling their players, along with a new chapter on ethical considerations. Aimed at readers with foundational AI knowledge, the book primarily targets three audiences: graduate or advanced undergraduate students pursuing careers in game AI, AI researchers and educators seeking teaching resources, and game programmers interested in creative AI applications. The text is complemented by a website featuring exercises, lecture slides, and additional educational materials suitable for undergraduate and graduate courses. |
| jnj annual report 2023: Equity Asset Valuation Jerald E. Pinto, Elaine Henry, Thomas R. Robinson, John D. Stowe, 2015-10-16 Navigate equity investments and asset valuation with confidence Equity Asset Valuation, Third Edition blends theory and practice to paint an accurate, informative picture of the equity asset world. The most comprehensive resource on the market, this text supplements your studies for the third step in the three-level CFA certification program by integrating both accounting and finance concepts to explore a collection of valuation models and challenge you to determine which models are most appropriate for certain companies and circumstances. Detailed learning outcome statements help you navigate your way through the content, which covers a wide range of topics, including how an analyst approaches the equity valuation process, the basic DDM, the derivation of the required rate of return within the context of Markowitz and Sharpe's modern portfolio theory, and more. Equity investments encompass the buying and holding of shares of stock in the anticipation of collecting income from dividends and capital gains. Determining which shares will be profitable is key, and an array of valuation techniques is applied on today's market to decide which stocks are ripe for investment and which are best left out of your portfolio. Access the most comprehensive equity asset valuation text on the market Leverage detailed learning outcome statements that focus your attention on key concepts, and guide you in applying the material accurately and effectively Explore a wide range of essential topics, such as the free cash flow approach, valuation using Graham and Dodd type concepts of earning power, associated market multiples, and residual income models Improve your study efforts by leveraging the text during your CFA certification program prep Equity Asset Valuation, Third Edition is a comprehensive, updated text that guides you through the information you need to know to fully understand the general analysis of equity investments. |
| jnj annual report 2023: Global Versus Local Perspectives on Finance and Accounting David Procházka, 2019-02-28 This proceedings volume examines accounting and financial issues and trends from both global and local economic perspectives. Featuring selected contributions presented at the 19th Annual Conference on Finance and Accounting (ACFA) held in Prague, Czech Republic, this book offers a mixture of research methods and micro- and macroeconomic approaches to depict a detailed picture of the impact of global and local determinants on the globalized economy. The global perspectives versus local specifics make the volume useful for not only academics and scholars, but also for regulators and policy makers when deliberating the potential outcome of competing regulatory mechanisms. The Annual Conference on Finance and Accounting (ACFA) has become one of the biggest conferences in the Central and Eastern European (CEE) region solely oriented to contemporary research in finance and accounting. Bringing together researchers and scholars from all over the world, the conference provides a platform in which thoughts, visions, and contemporary developments in the field of finance and accounting are discussed. |
| jnj annual report 2023: Patent Term Adjustments (Us Patent and Trademark Office Regulation) (Pto) (2018 Edition) The Law The Law Library, 2018-11-26 Patent Term Adjustments (US Patent and Trademark Office Regulation) (PTO) (2018 Edition) The Law Library presents the complete text of the Patent Term Adjustments (US Patent and Trademark Office Regulation) (PTO) (2018 Edition). Updated as of May 29, 2018 The United States Patent and Trademark Office (Office) is revising the rules of practice pertaining to patent term adjustment in view of the decision by the U.S. Court of Appeals for the Federal Circuit (Federal Circuit) in Novartis AG v. Lee. The Federal Circuit confirmed in Novartis that any time consumed by continued examination is subtracted in determining the extent to which the period of application pendency exceeds three years, regardless of when the continued examination was initiated. The Federal Circuit, however, decided that the time consumed by continued examination does not include the time after a notice of allowance, unless the Office actually resumes examination of the application after allowance. Accordingly, the Office is revising the rules of practice to provide that the time consumed by continued examination does not include the time after a notice of allowance, unless the applicant files a request for continued examination after such allowance. The Office also is revising the rules of practice to provide that the submission of a request for continued examination after any notice of allowance has been mailed will constitute a failure of an applicant to engage in reasonable efforts to conclude processing or examination of an application and thus result in a reduction of any period of patent term adjustment. The Office is providing an exception to this patent term adjustment reduction provision for a request for continued examination filed solely to submit information cited in a patent office communication in a counterpart application that is submitted to the Office within thirty days of receipt of the patent office communication. Additionally, the Office is clarifying what papers may be submitted after a notice of allowance without the applicant being considered to have failed to engage in reasonable efforts to conclude processing or examination of the application. This book contains: - The complete text of the Patent Term Adjustments (US Patent and Trademark Office Regulation) (PTO) (2018 Edition) - A table of contents with the page number of each section |
| jnj annual report 2023: Microbial Threats to Health Institute of Medicine, Board on Global Health, Committee on Emerging Microbial Threats to Health in the 21st Century, 2003-08-25 Infectious diseases are a global hazard that puts every nation and every person at risk. The recent SARS outbreak is a prime example. Knowing neither geographic nor political borders, often arriving silently and lethally, microbial pathogens constitute a grave threat to the health of humans. Indeed, a majority of countries recently identified the spread of infectious disease as the greatest global problem they confront. Throughout history, humans have struggled to control both the causes and consequences of infectious diseases and we will continue to do so into the foreseeable future. Following up on a high-profile 1992 report from the Institute of Medicine, Microbial Threats to Health examines the current state of knowledge and policy pertaining to emerging and re-emerging infectious diseases from around the globe. It examines the spectrum of microbial threats, factors in disease emergence, and the ultimate capacity of the United States to meet the challenges posed by microbial threats to human health. From the impact of war or technology on disease emergence to the development of enhanced disease surveillance and vaccine strategies, Microbial Threats to Health contains valuable information for researchers, students, health care providers, policymakers, public health officials. and the interested public. |
| jnj annual report 2023: Princípios de Marketing Kotler, Philip, Armstrong, Gary, 2023-03-09 A 18ª edição de Princípios de marketing reflete as principais tendências e forças de mudança que impactam o marketing nesta era digital, apresentando ferramentas para que os profissionais compreendam as necessidades e os desejos do consumidor e possam, assim, criar e desenvolver uma proposta de valor para ele, promovendo engajamento e retenção desses clientes. Complementado por inúmeros casos de empresas globais e trazendo uma cobertura revisitada e atualizada das tecnologias de marketing digital, bem como das mídias on-line, móvel e social, este é um livro de consulta indispensável para estudantes, empreendedores e profissionais das mais diversas áreas que desejam desenvolver uma estratégia de marketing para criar vantagem competitiva. |
| jnj annual report 2023: Standard & Poor's Stock Reports , 2004-04 |
| jnj annual report 2023: Private Patents and Public Health Ellen F. M. 't Hoen, 2016 Millions of people around the world do not have access to the medicines they need to treat disease or alleviate suffering. Strict patent regimes introduced following the establishment of the World Trade Organization in 1995 interfere with widespread access to medicines by creating monopolies that keep medicines prices well out of reach for many. 0The AIDS crisis in the late nineties brought access to medicines challenges to the public?s attention, when millions of people in developing countries died from an illness for which medicines existed, but were not available or affordable. Faced with an unprecedented health crisis ? 8,000 people dying daily ? the public health community launched an unprecedented global effort that eventually resulted in the large-scale availability of low-priced generic HIV medicines. 0But now, high prices of new medicines - for example, for cancer, tuberculosis and hepatitis C - are limiting access to treatment in low-, middle and high-income countries alike. Patent-based monopolies affect almost all medicines developed since 1995 in most countries, and global health policy is now at a critical juncture if the world is to avoid new access to medicines crises. 0This book discusses lessons learned from the HIV/AIDS crisis, and asks whether actions taken to extend access and save lives are exclusive to HIV or can be applied more broadly to new global access challenges. |
| jnj annual report 2023: Cytotoxic Payloads for Antibody–Drug Conjugates David E Thurston, Paul J M Jackson, 2019-07-15 Antibody–drug conjugates (ADCs) represent one of the most promising and exciting areas of anticancer drug discovery. Five ADCs are now approved in the US and EU [i.e., ado-trastuzumab emtansine (Kadcyla™), brentuximab vedotin (Adcetris™), inotuzumab ozogamicin (Besponsa™), gemtuzumab ozogamicin (Mylotarg™) and moxetumomab pasudotox-tdfk (Lumoxiti®)] and over 70 others are in various stages of clinical development, with impressive interim results being reported for many. The technology is based on the concept of delivering a cytotoxic payload selectively to cancer cells by attaching it to an antibody targeted to antigens on the cell surfaces. This approach has several advantages including the ability to select patients as likely responders based on the presence of antigen on the surface of their cancer cells and a wider therapeutic index, given that ADC targeting enables a more efficient delivery of cytotoxic agents to cancer cells than can be achieved by conventional chemotherapy, thus minimising systemic toxicity. Although there are many examples of antibodies that have been developed for this purpose, along with numerous linker technologies used to attach the cytotoxic agent to the antibody, there is presently a relatively small number of payload molecules in clinical use. The purpose of this book is to describe the variety of payloads used to date, along with a discussion of their advantages and disadvantages and to provide information on novel payloads at the research stage that may be used clinically in the future. |
| jnj annual report 2023: Highlights of Progress in Research on Cancer , 1960 |
| jnj annual report 2023: Fundamental Analysis For Dummies Matthew Krantz, 2009-10-06 How to determine the true strength and stability of any business What's the key to multibillionaire Warren Buffett's five-decade run as the most successful investor in history? Fundamental analysis. Now, Fundamental Analysis For Dummies puts this tried and true method for gauging any company's true underlying value into sensible and handy step-by-step instructions.. In this easy-to-understand, practical, and savvy guide you'll discover why this powerful tool is particularly important to investors in times of economic downturn and how it helps you assess a business's overall financial performance by using historical and present data to forecast its future monetary value. You'll also learn how to use fundamental analysis to spot bargains in the market, minimize your risk, and improve your overall investment skills. Shows how to predict the future value of a business based on its current and historical financial data Helps you guage a company's performance against its competitors Covers evaluation of internal management Reveals how to determine if in a company's credit standing is any jeopardy Applies fundamental analysis to other investment vehicles, including currency, bonds, and commodities Matt Krantz is a writer and reporter for USA TODAY and USATODAY.COM where he covers investments and financial markets Read Fundamental Analysis For Dummies and find the bargains that could make you the next Warren Buffett! |
| jnj annual report 2023: Report on Executive Compensation United States. Office of Wage Stabilization. Executive Compensation Branch, 1974 |
| jnj annual report 2023: Official List of Section 13(f) Securities , |
| jnj annual report 2023: Employee Training and Development Raymond A. Noe, 2005 Seeks to find a balance between research and company practices. This text provides students with a background in the fundamentals of training and development - needs assessment, transfer of training, designing a learning environment, methods, and evaluation. |
| jnj annual report 2023: Media Arabic Elisabeth Kendall, 2012-06-06 Gives you up-to-date expressions, jargon and new coinages for modern concepts in media Arabic. What is the Arabic term for the UN? What phrase would be used to describe 'rogue state' in the Arab media? Or 'the Arab Spring'? This short, accessible vocabulary gives you ready-made lists of key terms in media Arabic for translating both from and into Arabic. It is divided into 8 key areas:* General (reports, statements, sources, common media idioms)* Politics & Government* Elections* Military* Law and Order* Economics* Trade & Industry* Aid & DevelopmentThis second edition has been revised and updated throughout and now includes an English-Arabic index as well as audio and elearning materials.Key Features:* Terms grouped in thematic sections* Easy-to-learn lists to test translation* CD of audio files to help you check your pronunciation* Online interactive audio-visual e-Flashcards* IndexKeywords: Arabic; media Arabic; learn Arabic; teach Arabic; fast Arabic; quick Arabic; easy Arabic; newspaper Arabic; "e;how to say"e; Arabic. |
| jnj annual report 2023: Total Knee Arthroplasty James Alan Rand, 1993 This comprehensive reference on total knee arthroplasty describes all surgical techniques and prosthetic designs for primary and revision arthroplasty, discusses every aspect of patient selection, preoperative planning, and intraoperative and postoperative care. |
| jnj annual report 2023: Hyperopia and Presbyopia Kazuo Tsubota, Brian S. Boxer Wachler, Dimitri T. Azar, Douglas Koch, 2003-05-16 Examining established and emerging treatments for the correction of hyperopia and presbyopia, this reference offers guidance on technologies such as thermal or conductive keratoplasty, corneal implants, laser scleral relaxation, scleral expansion rings, intraocular lenses, and LASIK modifications. |
| jnj annual report 2023: Block’s Disinfection, Sterilization, and Preservation Gerald McDonnell, 2020-06-26 With more international contributors than ever before, Block’s Disinfection, Sterilization, and Preservation, 6th Edition, is the first new edition in nearly 20 years of the definitive technical manual for anyone involved in physical and chemical disinfection and sterilization methods. The book focuses on disease prevention—rather than eradication—and has been thoroughly updated with new information based on recent advances in the field and understanding of the risks, the technologies available, and the regulatory environments. |
| jnj annual report 2023: Modern Methods of Antiseptic Wound Treatment Johnson & Johnson, 2021-09-09 This work has been selected by scholars as being culturally important and is part of the knowledge base of civilization as we know it. This work is in the public domain in the United States of America, and possibly other nations. Within the United States, you may freely copy and distribute this work, as no entity (individual or corporate) has a copyright on the body of the work. Scholars believe, and we concur, that this work is important enough to be preserved, reproduced, and made generally available to the public. To ensure a quality reading experience, this work has been proofread and republished using a format that seamlessly blends the original graphical elements with text in an easy-to-read typeface. We appreciate your support of the preservation process, and thank you for being an important part of keeping this knowledge alive and relevant. |
| jnj annual report 2023: Corporate Finance Jonathan B. Berk, Peter M. DeMarzo, 2020 |
| jnj annual report 2023: Technological Innovation Marie C. Thursby, 2016-08-23 This is the 2nd edition of Technological Innovation. Profiting from technological innovation requires scientific and engineering expertise, and an understanding of how business and legal factors facilitate commercialization. This volume presents a multidisciplinary view of issues in technology commercialization and entrepreneurship. |
Johnson & Johnson (JNJ) - Yahoo Finance
Find the latest Johnson & Johnson (JNJ) stock quote, history, news and other vital information to help you with your stock trading and investing.
Johnson & Johnson: Changing health for humanity
Johnson & Johnson Innovative Medicine is leading where medicine is going. Patients inform and inspire our science-based innovations, which continue to change and save lives. With rigorous …
JNJ Stock Price | Johnson & Johnson Stock Quote (U.S.: NYSE)
4 days ago · JNJ | Complete Johnson & Johnson stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
Our company - Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for almost 140 years, we have aimed to keep …
Johnson & Johnson - Wikipedia
Johnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey, and publicly …
Investor Relations | Johnson & Johnson
6 days ago · At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated and …
Corporate | Johnson & Johnson - investor.jnj.com
1-800-950-5089 investor-relations@its.jnj.com. About us. Leadership Team; Office of The Chief Medical Officer; Announcements; Media Center; Our commitments. Code of Business …
Johnson & Johnson Increases U.S. Investment to More than $55 …
Mar 21, 2025 · New Brunswick, N.J. – MARCH 21, 2025 – Today, Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, …
Johnson & Johnson Common Stock (JNJ) Stock Price, Quote, News …
Discover real-time Johnson & Johnson Common Stock (JNJ) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead with Nasdaq.
Johnson & Johnson's dual-targeting CAR T-cell therapy shows …
4 days ago · Johnson Johnson (NYSE: JNJ) announced today the first clinical data from an ongoing Phase 1b study for JNJ-90014496 (JNJ-4496), an investigational dual-targeting anti …
Johnson & Johnson (JNJ) - Yahoo Finance
Find the latest Johnson & Johnson (JNJ) stock quote, history, news and other vital information to help you with your stock trading and investing.
Johnson & Johnson: Changing health for humanity
Johnson & Johnson Innovative Medicine is leading where medicine is going. Patients inform and inspire our science-based innovations, which continue to change and save lives. With rigorous …
JNJ Stock Price | Johnson & Johnson Stock Quote (U.S.: NYSE)
4 days ago · JNJ | Complete Johnson & Johnson stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
Our company - Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for almost 140 years, we have aimed to keep …
Johnson & Johnson - Wikipedia
Johnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey, and publicly traded on …
Investor Relations | Johnson & Johnson
6 days ago · At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated and …
Corporate | Johnson & Johnson - investor.jnj.com
1-800-950-5089 investor-relations@its.jnj.com. About us. Leadership Team; Office of The Chief Medical Officer; Announcements; Media Center; Our commitments. Code of Business Conduct; …
Johnson & Johnson Increases U.S. Investment to More than $55 …
Mar 21, 2025 · New Brunswick, N.J. – MARCH 21, 2025 – Today, Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, announced …
Johnson & Johnson Common Stock (JNJ) Stock Price, Quote, …
Discover real-time Johnson & Johnson Common Stock (JNJ) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead with Nasdaq.
Johnson & Johnson's dual-targeting CAR T-cell therapy shows …
4 days ago · Johnson Johnson (NYSE: JNJ) announced today the first clinical data from an ongoing Phase 1b study for JNJ-90014496 (JNJ-4496), an investigational dual-targeting anti …
